Abstract 2105
Background
Extracellular matrix (ECM) is a basic step of tumor invasion and metastasis. Matrix metalloproteinase (MMPs) family is a kind of zinc-ion-dependent endopeptidase, which can degrade almost all protein components in the extracellular matrix, destroy the histological barrier of tumor cell invasion, and play a key role in tumor invasion and metastasis. The role of MMP-9 in tumor invasion and metastasis has attracted increasing attention and is considered as the main proteolytic enzyme in this process. The aim of this study was to investigate the role of MMP-9 in human oral squamous cell carcinoma cells.
Methods
Human oral squamous cell carcinoma (OSCC) cells CAL27 and SCC-15 were cultured in DMEM high glucose medium with 10% FBS. The MMP-9-shRNA Lentiviral clone and control virus was constructed and transfected into OSCC cells. Cell proliferation was detected by MTT assay. Colony formation was evaluated by colony formation assay. Cell migration and invasion was evaluated using the scratch assay and transwell invasion assay. OSCC cells Knockdown with MMP-9-shRNA were injected into zebra fish and OSCC tumor model in zebra fish was established and evaluated.
Results
MMP-9 expression was down regulated significantly in RNA and protein level after transfection. Knockdown of MMP-9 gene by shRNA could inhibit oral squamous cell cancer cells growth and colony formation, and markedly suppress cell migration and invasion in vitro. And also knockdown of MMP-9 gene could significantly inhibit OSCC cells metastasis in zebra fish.
Conclusions
MMP-9 plays an important role in OSCC cells metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beijing Stomatological Hospital & School of Stomatology, Capital Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results
Presenter: David Berz
Session: Poster Display session 1
Resources:
Abstract
2853 - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Presenter: Petros Christopoulos
Session: Poster Display session 1
Resources:
Abstract
1974 - A Phase II Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients with Activating Epidermal Growth Factor Receptor mutation (EGFRm) from Circulating Tumor DNA (CtDNA)
Presenter: Young-Chul Kim
Session: Poster Display session 1
Resources:
Abstract
3370 - Influence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patients
Presenter: Geerten Veerman
Session: Poster Display session 1
Resources:
Abstract
5900 - PTEN loss as Predictor of Tumor Heterogeneity (TH) and Poor Prognosis in EGFR-mutant Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients (pts) Receiving Tyrosine-Kinase Inhibitors (TKIs).
Presenter: Miriam Ferrara
Session: Poster Display session 1
Resources:
Abstract
1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial
Presenter: Dae Ho Lee
Session: Poster Display session 1
Resources:
Abstract
2349 - The safety assessment of crizotinib and alectinib from real world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).
Presenter: Kei Kunimasa
Session: Poster Display session 1
Resources:
Abstract
1120 - Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the Use Via Expanded Access to Brigatinib (UVEA-Brig) study
Presenter: Silvia Novello
Session: Poster Display session 1
Resources:
Abstract
5239 - Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice
Presenter: Matthew Krebs
Session: Poster Display session 1
Resources:
Abstract